Compare LNC & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNC | RGEN |
|---|---|---|
| Founded | 1905 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | LNC | RGEN |
|---|---|---|
| Price | $41.67 | $150.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $45.92 | ★ $177.18 |
| AVG Volume (30 Days) | ★ 1.7M | 646.4K |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ 626.01 | N/A |
| EPS | ★ 11.17 | 0.03 |
| Revenue | ★ $18,426,000,000.00 | $707,890,000.00 |
| Revenue This Year | $6.91 | $17.86 |
| Revenue Next Year | $5.57 | $12.44 |
| P/E Ratio | ★ $3.72 | $4,837.83 |
| Revenue Growth | ★ 35.24 | 11.74 |
| 52 Week Low | $27.58 | $102.97 |
| 52 Week High | $46.82 | $177.17 |
| Indicator | LNC | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 33.52 |
| Support Level | $40.73 | $160.22 |
| Resistance Level | $42.08 | $174.87 |
| Average True Range (ATR) | 1.07 | 7.03 |
| MACD | -0.04 | -1.62 |
| Stochastic Oscillator | 63.57 | 2.98 |
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.